A Phase 3 Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2017

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms SECRET of CHF
  • Most Recent Events

    • 12 Mar 2017 Primary endpoint (Change in self-assessed dyspnea score, assessed at 8 and 16 h, by a 7-point Likert scale) has not been met, according to results published in the Journal of the American College of Cardiology.
    • 12 Mar 2017 Results published in the Journal of the American College of Cardiology.
    • 26 Sep 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top